Determination of expression of regulatory cells of cell cycle S phase in patients with gastric adenocarcinoma with oral administration of PUFAs before and after chemotherapy

Gastric cancer is the 5th most common cancer and the third cause of death in the world. Studies have shown that gastric cancer is somewhat susceptible to chemotherapy, but the duration of tumour reduction is short, and patients have not had much success in survival, and in many cases, chemotherapy resistance has been observed. Therefore, the main objective of this study was to investigate the effect of omega-unsaturated fatty acids on the expression of Cyclin A2, and CDK2 germ cell cycle in patients with gastric adenocarcinoma under chemotherapy.

This is a double-blind, pre-and post-test clinical trial with the target population of patients with gastric adenocarcinoma that were first identified and subjected to chemotherapy. Twenty-four patients were selected randomly and randomly in control and control groups. In the control group, the treatment was routine with cisplatin plus placebo. In the case group, treatment with cisplatin plus a supplement of natural fatty acid supplementation capsules of Ultimate-Omega Factors with a dose of 1200 mg per day was 3,600 mg Three tablets of 1200 mg (for three courses) started on horizons three weeks. Three samples of stomach biopsy were taken from all patients before and after chemotherapy. Biopsy specimens were extracted from all tissue mRNAs and cDNA was synthesized from them, and then the expression of the genes was measured using Real-Time PCR. The results were analyzed by SPSS software version 24.

The mean or average expression of Cyclin A2, CDK2 in the case group showed a significant decrease compared to the control group (P value was 0.021 and 0.026, respectively.

The results of this study showed that the use of omega-3, 6, 9 fatty acids with cisplatin can be useful in stopping the S-cell cycle in gastric cancer cells.